We believe Creo Medical's portfolio of products has the potential to transform cancer treatment, validated by early clinical outcomes. We forecast group revenues of c£100m by FY27E, with a significant contribution from Speedboat and associated products for upper and lower gastrointestinal (GI) procedures. Importantly, we include only c£9m of revenues from Kamaptive licensing, which we believe leaves significant upside given the scale and commercial reach of Intuitive, in particular. We believe t ....
17 Feb 2023
Cenkos: Creo Medical Group Plc -- Transforming cancer treatment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc -- Transforming cancer treatment
Creo Medical Group Plc (CREO:LON) | 34.8 0 0.0% | Mkt Cap: 125.6m
- Published:
17 Feb 2023 -
Author:
Chris Donnellan -
Pages:
31
We believe Creo Medical's portfolio of products has the potential to transform cancer treatment, validated by early clinical outcomes. We forecast group revenues of c£100m by FY27E, with a significant contribution from Speedboat and associated products for upper and lower gastrointestinal (GI) procedures. Importantly, we include only c£9m of revenues from Kamaptive licensing, which we believe leaves significant upside given the scale and commercial reach of Intuitive, in particular. We believe t ....